Loading organizations...
Loading organizations...
Sonoma Biotherapeutics has raised $340.0M across 3 funding rounds.
Sonoma Biotherapeutics has raised $340.0M in total across 3 funding rounds.
Sonoma Biotherapeutics has raised $340.0M in total across 3 funding rounds.
Sonoma Biotherapeutics's investors include ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, VZVC.
Sonoma Biotherapeutics is a biotechnology company developing engineered regulatory T cell (Treg) therapies to restore immune system balance and cure autoimmune and inflammatory diseases.[1][2][3] Founded in 2019 and headquartered in South San Francisco and Seattle, it targets patients with conditions like autoimmune disorders by harnessing patients' own immune cells, advanced gene editing, and manufacturing processes for durable, disease-modifying treatments.[1][3][6] The company serves patients underserved by current symptom-managing drugs, addressing immune dysregulation through curative cell therapies now advancing in clinical trials, with strong early momentum from $40 million Series A funding and Nobel-recognized science.[1][3]
Sonoma Biotherapeutics launched in February 2020 with $40 million in Series A financing from leading biotech investors, co-founded by four pioneers in Treg cell biology: Jeffrey Bluestone, PhD (CEO and President), Fred Ramsdell, PhD (CSO), and two others specializing in tolerance and cell therapy.[3][6] Bluestone, a leading immunologist from UCSF with expertise in T-cell activation, immune tolerance, and therapies like the first FDA-approved T-cell co-stimulation drug for autoimmunity, drove the vision after decades of research on IL-2 pathways and Tregs.[3][4][6] Ramsdell's 2025 Nobel Prize in Physiology or Medicine for discovering Tregs and the FOXP3 gene provided pivotal validation, building on his foundational work that revolutionized immune regulation.[1] Early traction came from assembling a world-class team of scientists, clinicians, and executives, plus proprietary platforms in genome editing and manufacturing to extend Treg therapies beyond cancer into autoimmunity.[3][6]
Sonoma rides the cell and gene therapy wave, shifting autoimmune treatment from chronic suppression to immune reset amid rising demand for curative biologics in a market projected to grow with aging populations and unmet needs in diseases like lupus and IBD.[1][4] Timing aligns with maturing Treg science post-Nobel recognition and clinical successes in oncology cell therapies, enabling cross-application to inflammation where current drugs fall short.[1][3] Favorable forces include investor enthusiasm for precision medicine, regulatory progress in personalized cells, and biotech hubs in San Francisco/Seattle fostering talent and partnerships.[3][6] Sonoma influences the ecosystem by pioneering Tregs for non-oncology uses, validating adoptive therapies, and collaborating to scale manufacturing—potentially establishing a new pillar of medicine.[4]
Sonoma's clinical trials for lead Treg programs position it for key readouts that could prove curative potential, with expansion into more autoimmune indications and manufacturing optimizations driving growth.[1][3] Trends like AI-aided gene editing, combo therapies, and regulatory incentives for rare diseases will accelerate progress, while partnerships may fuel late-stage trials. Its influence could evolve from Treg pioneer to category leader, transforming patient lives through durable cures and inspiring immune therapy innovation—restoring balance as the key to unlocking broader medical breakthroughs.[1][2][5]
Sonoma Biotherapeutics has raised $340.0M across 3 funding rounds. Most recently, it raised $270.0M Series B in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $270.0M Series B | ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, VZVC | |
| Sep 1, 2020 | $30.0M Series A | ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, VZVC | |
| Feb 1, 2020 | $40.0M Series A | ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, VZVC |
